MedMira Laboratories Inc. – Trademark Portfolio
Entity Type: 03
MedMira Laboratories Inc. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 10 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include REVEAL, MULTIPLO, and RAPID VERTICAL FLOW TECHNOLOGY. The owner is based in Halifax, Nova Scotia.
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S1B3 , CA
Showing of trademarks Trademarks
Trademark Classifications
MedMira Laboratories Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does MedMira Laboratories Inc. have?
MedMira Laboratories Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 7 cancelled.
What trademark classes does MedMira Laboratories Inc. file in?
MedMira Laboratories Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are MedMira Laboratories Inc.'s most well-known trademarks?
MedMira Laboratories Inc.'s registered trademark portfolio includes well-known marks such as REVEAL, MULTIPLO, and RAPID VERTICAL FLOW TECHNOLOGY. These are among 3 currently registered trademarks in the portfolio.
What is MedMira Laboratories Inc.'s trademark registration success rate?
MedMira Laboratories Inc. has a 27% trademark registration rate, with 3 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.